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Background: Chemoradiotherapy (CRT) is an effective modality for stage I esophageal squamous cell carcinoma
(ESCC). However, salvage treatments are often required even if complete response (CR) has been achieved. To this
end, it is important to accurately diagnose lymph node or other organ metastatic recurrences. Note that lymph
node enlargements (except metastatic recurrence) are often detected during the follow-up period after CRT. The
purpose of this study was to elucidate the clinical characteristics of lymph node enlargement after CRT.
Methods: In this retrospective cohort study, patients diagnosed with stage I (T1 [submucosal invasion] N0M0) ESCC
were treated with cisplatin and 5-fluorouracil concurrently with radiotherapy. A total of 55 patients were enrolled in
the study from February 2006 to August 2011.
Results: The median follow-up period was 46 months. The 3-year overall and progression-free survival rates were
90.7% and 71.2%, respectively, and the CR rate was 87.2% (48/55). Nine of the 48 CR patients were finally diagnosed
with recurrences, including 7 lymph node metastases and 2 local recurrences. Lymph node enlargement was initially
identified in 20 of the total 55 patients during the follow-up; 9 patients were finally diagnosed with lymph node
recurrence, whereas 11 patients had benign reactive lymph node enlargement.
Conclusion: The present study demonstrated the high incidence of enlarged lymph nodes after CRT for stage I ESCC.
It is important to accurately distinguish between benign lymph node enlargement and recurrent lymph nodes to
avoid unnecessary salvage treatments.
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Esophageal carcinoma is the major cause of cancer-
related mortality in the world and also in Japan [1]. Sur-
gical esophagectomy with lymphadenectomy is consid-
ered to be the standard treatment for patients in clinical
stages I to III ESCC [2,3]. Recent improvements of
endoscopic techniques (non-surgical treatments) have
allowed organ preservation in patients with mucosal
ESCC. However, endoscopic resection (ER) is not indi-
cated for ESCC with submucosal invasion. Moreover,* Correspondence: takehara@gh.med.osaka-u.ac.jp
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reproduction in any medium, provided the orthere is a high incidence of lymph node occult metasta-
sis in 10% to 30% of the patients with submucosal can-
cer. Today, these patients are usually treated surgically.
The survival rate of patients with submucosal tumors
treated surgically at 3 years is > 80%, but esophagectomy
is an invasive procedure and has the risk of postopera-
tive morbidity. For the patients in stages II and III
ESCC, postoperative chemotherapy is superior to sur-
gery alone in disease free survival and preoperative
chemotherapy leads to the superiority to postoperative
chemotherapy in overall survival [4,5], which suggests
that chemotherapy is efficacious in suppressing lymph
node recurrences. Several reports have recently con-
firmed that concurrent chemoradiotherapy (CRT) is al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ESCC, compared to radiotherapy alone [6-8]. CRT is
considered to be less invasive because of the better qual-
ity of life after the treatment compared to esophagec-
tomy. Definitive CRT is considered to have an indication
not only for the advanced stage but for the early stage as
well [9-11]. A phase II study has demonstrated that de-
finitive CRT is a favorable alternative to esophagectomy
in patients with clinical stage I ESCC [10,12].
CRT seems to be an effective modality, particularly for
submucosal ESCC without lymph node metastasis. How-
ever, it is known that patients with submucosal invasion
have invisible lymph node metastases at the time of
diagnosis. Accordingly, they are considered to be at high
risk for lymph node recurrence after CRT, and salvage
treatments are often required to improve their survival,
although they had achieved complete response (CR). To
detect metastatic or recurrent lesions as soon as pos-
sible, endoscopy and thoraco-abdominal computed tom-
ography (CT) are regularly performed for monitoring
after CRT. If a recurrence occurred locally in the muco-
sal layer, it is easy to diagnose with endoscopic biopsy
and ER is a useful salvage modality to control in such
cases. On the contrary, it is difficult to accurately diag-
nose lymph node recurrence after CRT because little is
known about the recurrence pattern after CRT for pa-
tients with clinical stage I ESCC. We experienced several
cases in which lymph node enlargements were detected
after CRT. Although surgical esophagectomy was per-
formed in the early period, we observed that a few cases
were pathologically benign, which suggested that benign
lymph node enlargement that was reactive to the treat-
ment might mimic metastasis in certain cases. The aim
of this study was to elucidate the clinical characteristics
of lymph node enlargement after CRT.
Methods
Patient population
This retrospective study used the database at the De-
partment of Gastroenterology and Hepatology of Osaka
University Hospital. From February 2006 to August 2011,
55 consecutive patients with stage I (T1 [submucosal
cancer] N0 M0) ESCC who were treated with CRT were
analysed. TNM staging was determined according to the
Union for International Cancer Control criteria. None of
the patients chose the surgical treatment. The median pa-
tient age was 66 years (range, 49–82 years). The clinical
stage was diagnosed by endoscopy, endoscopic ultra-
sonography, cervical and thoraco-abdominal CT. Tumor
localization was identified by combining chromoendo-
scopy with Lugol staining. Tumor invasion depth was
evaluated using magnification endoscopy with narrow
band imaging (NBI) and endoscopic ultrasonography in
addition to conventional CT. The CRT was performed asfollowing criteria: 1) Eastern Cooperative Oncology Group
performance status of 0–2; 2) leucocyte count >3,000/m3,
platelet count >100,000/m3; 3) aspartate aminotransferase
or alanine transferase level within 3 times the normal
upper limit; 4) creatinine level <1.5 mg/dl and creatinine
clearance >50 ml/min; and 5) no other serious complica-
tions. All patients had adequate hepatic and renal functions
and performance status scores of 0. The tumor histological
type was diagnosed as squamous cell carcinoma based on
an endoscopic biopsy. This study was approved by the
Institutional Review Board of Osaka University.
Chemoradiotherapy
All patients were treated with cisplatin and 5-FU chemo-
therapy. Cisplatin was administered at a dose of 70 mg/
m2 body surface area on Day 1 and Day 29, and 5-FU
was administered at a dose of 700 mg/m2 per day by
continuous infusion for 24 hours on Days 1–5 and Days
29–33. Nedaplatin was administered instead of cisplatin
to 3 patients on Day 29 because of renal dysfunction in-
duced by cisplatin. The concurrent radiotherapy con-
sisted of external administrations of 2 Gy daily to a total
dose of 60 Gy without a planned break. The gross tumor
volume was limited to the primary tumor. The planning
target volume was defined by adding 2- to 3-cm margins
above and below the tumor without prophylactic lymph
node coverage according to the clips marked during the
endoscopic procedure. The lateral, anterior, and poster-
ior margins were limited to 1–2 cm. The radiation ther-
apy field comprised the planning target volume for up to
40 Gy with anterior/posterior opposed portals and ex-
posed to an additional 20 Gy with bilateral oblique por-
tals excluding the spinal cord.
Assessments of response, recurrence and toxicity
after CRT
After CRT, the clinical response was assessed with endo-
scopic observation accompanied by biopsy specimens
and a thoraco-abdominal multidetector CT scan. CR was
defined when a tumor was not detected by endoscopic
observation and CT scan for >4 weeks. First, the initial
evaluation was performed 1 month after CRT and subse-
quently followed up at 3-month intervals up to 1 year
and subsequently at 6 months and up to 5 years by en-
doscopy and thoraco-abdominal CT scan or until recur-
rence was diagnosed. Metachronous esophageal recurrence
out of the radiation field was not included in the present
study. A lymph node enlargement was defined when the
size of a lymph node was larger than the initial size before
CRT or newly detected by CT scan. The early cases were
diagnosed as a recurrence or a benign enlargement patho-
logically by surgical resection. In the later cases, the lymph
node enlargement was followed by CT scan with closed
interval. During the closed follow-up, the enlarged lymph
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in size and number in the CT scan. When the exacerbation
was not detected for more than 6 months, lymph node en-
largement was defined as “benign”.
Adverse events were retrospectively evaluated using the
Common Terminology Criteria version 4.0. We evaluated
therapeutic late toxicity according to the Radiation Ther-
apy Oncology Group/European Organization for Research
and Treatment of Cancer late radiation morbidity scoring
schema (available at http://www.rtog.org/).
Statistical analysis
If there were missing cases, the date of the last observa-
tion was defined as the censor date. The overall survival
was calculated using the Kaplan-Meier method from the
date of CRT initiation to death from any cause. Cumula-
tive progression-free survival was calculated using the
Kaplan-Meier method from the date of CRT initiation to
the recurrence or death from any cause. A Wilcoxon test
was performed to compare diameters and intervals until
lymph node enlargement between benign enlargement
and recurrence. All analyses were performed using JMP
software (V.10.0.2, SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
The median follow-up period after initiating CRT was
46 months (range, 2–83 months). The main clinical
characteristics of the patients are presented in Table 1.
Before the treatment, 5 patients had been treated for
malignancies in other organs, which were inactive when
CRT was performed for ESCC. During the follow-up
period, the second primary cancers in the other organs
were observed in 10 patients: pancreas, skin, and pros-
tate, 1; biliary duct, 1; urinary tract, 1; pharynx, 1; colon,
1; lung and stomach, 1; vocal cord and stomach, 1; valve,
1; thyroid, 1; and stomach, 1. Esophageal intraepithelial
neoplasia, which occurred metachronously out of theTable 1 Patient characteristics
Number of patients 55
Gender male/female 49/6
Age, median [range] (yrs) 66 [49–82]





Inactive multiple cancers in other organ
no/yes 50/5
Median follow-up period [range] (months) 46 [2–83]radiation therapy field, was detected in 3 patients after
CRT; all of whom were treated with ER.
Adherence and adverse events
All but 2 patients successfully underwent total treatment,
and the treatment completion rate was 96%. One of the 2
patients received only 52 Gy irradiation because he with-
drew further treatment, and the other patient received an
80% dose of chemotherapy on Days 29–33 because of
digestive toxicity. One patient died 2 weeks after CRT com-
pletion. The causal correlation with the treatment was not
confirmed; however, treatment-related death was suspected.
With regard to hematologic adverse events, grade 3 or 4
leukocytopenia was observed in 8 patients, and grade 3
anaemia was observed in 1 patient. Grade 3 appetite loss
and nausea were seen in 3 patients, and grade 3 mucositis
was observed in 3 patients. Late toxicity events were ob-
served 3 to 24 months after the treatment. Grade 3 inter-
stitial lung disease was observed in 1 patient (1.8%). Grade
3 pericardial effusions were observed in 3 patients (5.5%).
Two of these patients had been treated for cardiac disease
before CRT.
Treatment efficacy
The 3-year overall survival rate in all patients was 90.7%
(Figure 1a). The CR rate was 87.2% (48/55). Although 6
non-CR patients, except for 1 patient who was suspected
of treatment-related death, underwent salvage treatment,
including surgery and chemotherapy, 2 died because of
lymph node recurrence and liver metastasis (Table 2).
Of the 48 CR patients, 5 died from lymph node recur-
rences, and 4 patients died without ESCC recurrences
during the follow-up period: urinary tract cancer, 1; biliary
tract cancer, 1; sudden death of unknown cause, 1; and
acute heart failure, 1.
The 3-year progression-free survival rate was 71.2%
(Figure 1b). Of the 48 CR patients, recurrences were
detected in 9 patients from 8 to 41 months after CRT
initiation. The local recurrences of 2 patients were treated
completely with ER. Lymph node recurrences were
found in 7 patients who underwent salvage surgery or
chemotherapy. Of the limited 48 CR patients, the 3-year
progression-free survival rate was 81.5%.
Lymph node enlargement
We performed a scheduled thoraco-abdominal CT before
and after the treatment according to the protocol for de-
tecting metastatic recurrence. Although no enlarged lymph
node was detected by CT before CRT, the enlarged lymph
nodes were detected in 20 (36.3%) of the 55 patients during
the scheduled follow-up (Table 3). Initially, the salvage sur-
gery including lymphadenectomy for lymph node enlarge-
ments were performed in 4 patients. Two patients who
underwent surgery were pathologically diagnosed with
Figure 1 Treatment Efficacy of CRT. a. Cumulative overall survival curve. The 3-year overall survival rate was 90.7%. b. Cumulative progression-free
survival curve. The 3-year progression-free survival rate was 71.2%.
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tients with newly enlarged lymph nodes using CT to deter-
mine whether the nodes were metastatic recurrences.
Among the 20 patients in whom enlarged lymph nodes
were detected after CRT, 7 patients were diagnosed with
lymph node recurrences because of the additional growth
of lymph nodes within 6 months or surgical pathological
examinations. The size of the lymph nodes of 13 patients
did not change within 6 months, and they satisfied the
“benign” definition. However, in 2 patients, the lymph
nodes (patients 3 and 6) grew slowly and were finally diag-
nosed as metastatic recurrences more than 1 year after
their initial detections. Consequently, 9 of these 20 patients
(45%) were diagnosed with metastasis, and 11 patients
(55%) were considered to have reactive enlargement ofTable 2 Characteristics patients experiencing treatment failur
No. Tumor location Response Time to failure
1 Lt CR 41
2 Mt CR 30
3 Lt CR 30
4 Mt CR 28
5 Lt CR 20
6 Mt CR 20
7 Mt CR 10
8 Mt CR 8
9 Ut CR 8
10 Mt No CR 8
11 Mt No CR 5
12 Mt No CR 4
13 Mt No CR 4
14 Mt No CR 4
15 Mt No CR 3
UT, upper thoracic; MT, middle thoracic; LT, lower thoracic; LN, lymph node; ESD, enlymph nodes. The average interval from initiating CRT to
the point of lymph node enlargement was 14.1 months
in the patients with recurrent metastasis and 12.0 months
in the patients with benign lymph node enlargement. The
average lymph node diameters were 9.3 mm in the patients
with recurrent metastasis and 8.3 mm in the patients with
benign lymph node enlargement. We did not find signifi-
cant differences between the recurrence and the benign en-
largements in the interval after CRT or lymph node size.
The benign lymph node enlargements that were diagnosed
were followed for >19 months, except for 1 patient who
was followed for 8 months, which suggests that these pa-
tients had benign lymph node enlargements. Regarding the
benign lymph node enlargements, FDG accumulation on
PET-CT was positive in one patient and negative in 5e after CRT































1 Mt CR Mediastinum 21 mm 17 months 35 mm 3 months Positive SCC Surgery
2 Mt CR Supraclavicular 12 mm 19 months 20 mm 1 month Positive SCC Surgery
3 Lt CR Recurrent nerve/
supraclavicular
8 mm 27 months 12 mm 14 months Positive - Chemotherapy
4 Mt CR Cardia 8 mm 5 months 11 mm 5 months Positive - Chemotherapy
5 Mt CR Cervical
paraesophageal
7 mm 30 months 7 mm - Positive SCC Surgery
6 Mt CR Mediastinum/
supraclavicular
6 mm 14 months 12 mm 14 months Positive - Chemotherapy
7 Ut CR Recurrent nerve 6 mm 8 months 10 mm 2 months Positive SCC Surgery
8 Mt No CR Left gastric artery 10 mm 5 months 10 mm - Positive SCC Surgery












1 Lt CR Infradiaphragmatic 19 mm Negative 2 months - - 59 months
2 Lt CR Main bronchus 17 mm Negative 9 months 3 months - 64 months
3 Mt CR Mediastinum 10 mm Negative 19 months - - 22 months
4 Mt CR Recurrent nerve 10 mm Positive 16 months Up to surgery Benign 46 months
5 Mt CR Subcarinal 10 mm N.A. 29 months - - 19 months
6 Mt CR Supraclavicular 10 mm Negative 2 months 12 months - 60 months
7 Mt CR Superficial cervical 9 mm N.A. 39 months - - 8 months
8 Mt CR Recurrent nerve 9 mm N.A. 5 months Up to surgery Benign 78 months
9 Ut CR Main bronchus 8 mm N.A. 2 months 29 months - 68 months
10 Ut CR Cardia 6 mm Negative 4 months 7 months - 51 months
11 Mt CR Main bronchus 6 mm N.A. 3 months - - 33 months
UT, upper thoracic; MT, middle thoracic; LT, lower thoracic; LN, lymph node; SCC, squamous cell carcinoma; N.A., not assessed.
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enlarged lymph nodes diagnosed as metastatic recurrence
finally showed FDG accumulation. Regarding the alter-
ation of lymph node diameter after detecting lymph node
enlargement, we observed that several nodes shrank
promptly, whereas others maintained the same size during
the follow-up period. Half of the lymph node enlarge-
ments that occurred after CRT were eventually diagnosed
as false-positive, which means that they could avoid un-
necessary treatment.
Discussion
The current study demonstrated favourable therapeutic
outcomes, including CR rate, overall survival, and
progression-free survival, as previously reported, for the
ESCC patients treated with CRT [10]. More importantly,
the present study clearly demonstrated the high incidence
of lymph node enlargements found during the follow-up
after CRT.Salvage surgery was performed in the early cases as
soon as we detected an enlarged lymph node by CT
during the follow-up after CRT. However, we noticed
that in the pathological examination after surgery, be-
nign lymph node enlargements occasionally occurred
early in several cases. For the later cases, we closely
followed lymph node enlargement after CRT to deter-
mine the likelihood of a recurrence or of a benign en-
largement clinically. The present study indicated that
the benign enlargements accounted for >50% of all en-
larged lymph nodes detected by CT scan. Based on the
premise that benign lymph node enlargements are fre-
quently detected after CRT, we must distinguish recur-
rences from simple enlargements using non-invasive
modality. In the present study, we defined the lymph
node enlargement as “benign” when the exacerbation
was not detected for >6 months. However, 2 patients
finally suffered from metastatic lymph nodes, although
their enlarged lymph nodes were not exacerbated within
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necessary salvage esophagectomy and lymphadenectomy,
we must closely monitor patients with enlarged lymph
nodes. Additional studies regarding modalities, biomarkers,
or clinicopathological characteristics that discriminated
between lymph node enlargement and recurrence should
be performed.
With regard to feasibility, adverse events were toler-
able compared to the previous study [10]. However, we
must recognise the treatment risk after CRT, particularly
cardiac toxicity. One patient died within 3 months of
initiating treatment. Three patients suffered from cardiac
disease accompanied by pericardial effusion as adverse
events. We are uncertain whether CRT was directly re-
lated to the cardiac disease observed in these cases, be-
cause 2 of the 3 patients had been previously treated for
myocardial infarction or angina. Moreover, although
pericardial effusion was not induced, acute heart failure
occurred in 1 patient who had been previously treated
for angina, and 2 patients died suddenly from unknown
causes. In all cases, the primary tumors were located in
the inferior esophagus. The pericardial exposure with ra-
diation might have caused the cardiovascular events,
such as heart failure or arrhythmia. These results suggest
that we must pay particular attention to those patients
who have previous histories of cardiac diseases and in-
ferior esophageal tumors.
The present study has several limitations. First, this
is a retrospective study in a single hospital, and the
total patient population is small. Second, the mech-
anism of benign enlargements of lymph nodes is un-
certain. It is possible that the decrease of radiation
dose contributes the suppression of lymph node en-
largements. However, in the present study, lymph
node enlargements did not depend on whether they
included within or out of radiation field. Third, the
histological type of all patients enrolled in this study
was squamous cell carcinoma. It is uncertain whether
these findings shown in this manuscript are applic-
able to esophageal adenocarcinoma which is common
in Western countries.Conclusion
In conclusion, our study reveals that CRT is effective
and feasible for patients with clinical stage I ESCC and
that lymph node enlargements are often detected during
follow-up after CRT. Note that benign lymph node en-
largements comprise >50% of the enlarged lymph nodes
after CRT.
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